The development of antibody-based inhibitors targeting the PD-1/PD-L1 pathway has led to significant clinical success in treating various cancers, making PD-L1 expression on tumor cells and other cells in the tumor microenvironment highly relevant for clinical outcomes (21). This evidence concerns the gene PDCD1 and neoplasm.